Subscribe for UEG News

Sign up for our newsletter to stay up-to-date with the latest in digestive health in Europe and around the world. Get information on our online content and services, most of them free of charge, and don’t miss any deadlines.

Eating less salt may reduce the risk of stomach cancer: UEG calls for greater salt-awareness across Europe.

(Vienna January, 12, 2015) Stomach cancer is diagnosed in around 80,000 people in the European Union (EU) each year and is associated with a very poor prognosis. The most well-established risk factor for stomach cancer is infection with Helicobacter pylori (H. pylori), which causes inflammation within the stomach that can progress to stomach cancer.

Now scientists believe that eating too much salt also increases the risk of stomach cancer, with a direct relationship found between salt consumption and cancer risk. According to Professor John Atherton, UEG Secretary General and a leading H. pylori expert, the combination of H. pylori infection and a high salt intake appears to be especially dangerous. “Although we don’t know exactly why salt increases the risk of stomach cancer, studies suggest that it may encourage the growth of H. pylori and make it more toxic to the cells of the stomach,” he says.Stomach cancer in the EU
The recent Survey of Digestive Health Across Europe reported that more than 80,000 new cases of stomach cancer were identified in the EU in 2012, with twice as many men as women affected. H. pylori infection, which typically occurs during childhood and is difficult to detect, has been estimated to be responsible for around three-quarters of all stomach cancers. Excessive salt consumption is thought to contribute to a quarter of all cases.
“Most of us know that salt is associated with high blood pressure and an increased risk of heart disease and stroke,” says Prof. Atherton. “However, I suspect very few people are aware that a high-salt diet may also increase the risk of stomach cancer.”
Salt consumption guidelines
The European Commission and many individual European countries have taken positive action towards reducing salt consumption across the continent. Current guidelines from the World Health Organisation (WHO) suggest that no more than 5 g of salt (less than 1 teaspoon) should be eaten per day – a challenging target given that most salt in our diets is not added by us, but comes from processed foods such as bread, cheese, breakfast cereals and ready meals.
“In the UK, our salt target for adults is no more than 6 g per day, which should theoretically reduce the risk of stomach cancer as well as other salt-related health problems,” says Prof. Atherton. “Although we need more studies to confirm that eating a low-salt diet reduces the incidence of stomach cancer, there is preliminary evidence from Japan to suggest this would be the case.”
It is straightforward to reduce salt in your diet: take special care when shopping to, buy low-salt versions of your favourite foods; moderate your intake of some foods such as cured meat, bread, cheese and table sauces; and to add no salt during cooking or at the table. This will reduce your risk of a variety of diseases, particularly heart disease and stroke and it now looks as though it will also reduce your risk of developing stomach cancer.
References:
1. WHO International Agency for Research on Cancer. http://eu-cancer.iarc.fr/.
2. D’Elia L, Rossi G, Ippolito R, et al. Clin Nutr 2012;31(4):489–98.
3. Roberts SE, Samuel DG, Williams JG, et al. Survey of Digestive Health across Europe. Part one: The burden of gastrointestinal diseases and the organisation and delivery of gastroenterology services across Europe. Report for United European Gastroenterology. August 2014.
4. Parkin DM. Br J Cancer 2011;105:S31–S33.
5. Tominaga S, Kuroishi T. Int J Cancer 1997;10(Suppl):2–6.
6. World Action on Salt & Health. Salt and stomach cancer. Available at: http://www.worldactiononsalt.com/salthealth/factsheets/stomach/index.html. Last accessed 5 January 2015.
Notes to Editors
About UEG
UEG, or United European Gastroenterology, is a professional non-profit organisation combining all the leading European societies concerned with digestive diseases. Together, its member societies represent over 22,000 specialists, working across medicine, surgery, paediatrics, gastrointestinal oncology and endoscopy. This makes UEG the most comprehensive organisation of its kind in the world, and a unique platform for collaboration and the exchange of knowledge.
Find out more about UEG’s work, visit www.ueg.eu
Available for interview
UEG Spokesperson, Professor John Atherton is the UEG Secretary General and also a leading H. pylori expert at The University of Nottingham.
Press contact
Samantha Forster
media@ueg.eu
Tel: +44 (0)1444 811099
@UEGMedia

(Vienna December, 15, 2014) A new study, published in the latest issue of the UEG Journal reveals that 10% of IBD patients are misdiagnosed with IBS and in 3% of cases the misdiagnosis can persist for five or more years. The case-controlled study, conducted in the UK, assessed the proportion of patients with IBS recorded prior to the IBD diagnosis to reveal the alarming statistics.

Leading IBD researcher and United European Gastroenterology (UEG) spokesperson Dr Michael Scharl says, “IBS has been estimated to affect at least 10% of the population in Europe and it causes distressing symptoms that disrupt normal life.” He explains, “We have known for some time that there are similarities between symptoms of IBS and IBD, but when it comes to diagnosis and treatment, this differs greatly.”
He adds, “Misdiagnosis is understandable as many symptoms such as diarrhoea, abdominal cramping and pain are common to both and the specific alarm symptoms for IBD such as bloody stool, weight loss or fever are often absent in IBD patients in the initial phase of their disease. However, increased use of faecal calprotectin testing would help doctors distinguish between inflammatory bowel diseases, such as Crohn’s disease and ulcerative colitis and non-inflammatory bowel diseases, such as irritable bowel syndrome.”
IBS has been estimated to affect at least 10 of the population in Europe. The initial misdiagnosis of IBD has serious consequences for patients, in particular those with Crohn's disease, since delays in diagnosis is correlated with an increased risk of bowel stenosis and CD-related intestinal surgery. Considering that the misdiagnosis of IBD might have severe consequences for a patient’s life, UEG are calling for increased efforts to be undertaken to screen symptomatic IBS patients for IBD. Screening tests for intestinal inflammation should be included in the work up of all new patients presenting with diarrhoea and pain.
References:
1. Timothy R Card, Jesse Siffledeen and Kate M Fleming. Are IBD patients more likely to have a prior diagnosis of irritable bowel syndrome? Report of a case-control study in the General Practice Research Database. 2: 505-512, UEG Journal December 2014. Available at: http://ueg.sagepub.com/content/2/6/505.full
Notes to Editors
About UEG
UEG, or United European Gastroenterology, is a professional non-profit organisation combining all the leading European societies concerned with digestive diseases. Together, its member societies represent over 22,000 specialists, working across medicine, surgery, paediatrics, gastrointestinal oncology and endoscopy. This makes UEG the most comprehensive organisation of its kind in the world, and a unique platform for collaboration and the exchange of knowledge. Find out more about UEG’s work. Visit www.ueg.eu
Available for interview
UEG Spokesperson, Dr Michael Scharl is an expert in both IBS and IBD and has recently been awarded a ‘UEG Rising Star’ award for his research which opens avenues for completely new treatment strategies for IBD and Crohn’s disease.
Press contact
Samantha Forster
media@ueg.eu
Tel: +44 (0)1444 811099
@UEGMedia

UEG puts the need for better care for IBD patients in Europe on the political agenda.

(Vienna, December, 02, 2014) With inflammatory bowel disease (IBD) thought to cost the European Community over €2 billion in annual healthcare costs, United European Gastroenterology (UEG) is calling for EU politicians and leading decision-makers to take a more active role in reducing the burden of the disease.

Presenting the results of a major ‘Survey of Digestive Health Across Europe’, to the European Parliament in Brussels today, UEG aim to draw attention to the impact IBD and other digestive and liver diseases have on the health and economy of the European community.
The ‘Survey of Digestive Health across Europe’ highlights major differences in the incidence of gastrointestinal disorders and long-term health outcomes amongst European communities. Amongst IBD sufferers, incidence of Crohn’s disease was found to be highest in northern and western regions of Europe whilst ulcerative colitis had the highest incidence in Ireland, Denmark and Finland and the highest incidence of IBD overall is in France.
According to UEG President, Professor Michael Farthing, “IBD has an increasingly crippling impact both to society and to individuals, particularly, the huge proportion of young people who suffer. UEG aim to raise awareness amongst the European Parliament of the debilitating symptoms and resulting impact on quality of life and performance.”
As many as 30% of all IBD patients presenting with symptoms are between the ages of 10 and 19 and nearly a fifth of under 18 year olds have to wait more than 5 years to receive a final diagnosis. Symptoms of IBD include faecal incontinence, abdominal cramping and extreme fatigue often resulting in depression and low self-esteem. The ‘Survey of Digestive Health Across Europe’ reveals that 21% of IBD sufferers across Europe felt they had been discriminated against in the workplace with 44% reported to have lost or had to leave their job.
“The cost of IBD care has increased significantly over the past decade and it is vital that additional funding is made available to help reduce the health and societal burden of the disease through ensuring a quicker diagnosis and equitable access to the best treatment for all patients across Europe” adds Professor Farthing.
Notes to Editors:About UEG
United European Gastroenterology is a professional non-profit organisation combining all the leading European societies concerned with digestive diseases. Together, its member societies represent over 22,000 specialists, working across medicine, surgery, paediatrics, gastrointestinal oncology and endoscopy.
Find out more about UEG’s work at www.ueg.eu
UEG Events at European Parliament, Brussels – December 2nd, 2014
Digestive Health Survey and Healthcare in Europe 2040: Scenarios and Implications for Digestive and Liver Diseases presentations
Host/Chairs: MEP Pavel Poc and Professor Michael Farthing (UEG President)
“Inflammatory Bowel Disease: A rising threat to the health of young Europeans” Debate
Host/Chairs: MEPs Rebecca Harms/Michele Rivasi and Professor Theirry Ponchon (Chair, UEG Public Affairs Committee)
Survey of Digestive Health Across Europe
The Survey of Digestive Health Across Europe was commissioned by UEG in the spring of 2013 at the request of its own Future Trends Committee. An experienced research group from Swansea University in Wales, UK, initiated a detailed assessment of digestive health across Europe, focussing on the clinical and economic burden of disease and the organisation and delivery of gastroenterology services across 28 European Union (EU) member states, Norway, Switzerland, Liechtenstein and Russia. The aim of the survey was to draw together all the available evidence and provide up-to-date information on the human health consequences and public health burden of GI disorders.
Available for interview
Professor Michael Farthing, UEG President
Press contact
Samantha Forster
media@ueg.eu
Tel:+44(0)1444811099
@UEGMedia
References
1. Roberts SE, Samuel DG, Williams JG, et al. Survey of Digestive Health across Europe. Part one: The burden of gastrointestinal diseases and the organisation and delivery of gastroenterology services across Europe. Report for United European Gastroenterology. October 2014.
2. Anderson P, Dalziel K, Davies E et al. Survey of Digestive Health across Europe. Part two: The economic impact and burden of gastrointestinal diseases across Europe. Report for United European Gastroenterology. October 2014.
3. Problems in the diagnosis of IBD in children. H.A Buller. Paediatric Gastroenterology and Nutrition, Academic Medical Centre, University of Amsterdam – The Netherlands Journal of Medicine.
4. EFCCA Impact of IBD Study 2010-2011. Published J Crohns and Colitis. 2014 March 21
5. The Inflammatory Bowel Disease in Young People - The impact on education and employment report - downloadable from the www.crohnsandcolitis.org.uk

(November, 24, 2014) United European Gastroenterology (UEG) is supporting the second annual Awareness Week on Alcohol Related Harm (AWARH) and calls for greater awareness of the relationship between alcohol and liver cancer. Excessive alcohol consumption can lead to liver cancer, estimated to be responsible for 746,000 worldwide deaths each year, making it the second most common cause of cancer death.

Europe is by far the biggest drinking region in the world. According to a new pan-European Survey of Digestive Health commissioned by UEG, hospital admissions for alcoholic liver disease which is a key precursor to liver cancer have increased by more than 120% since 1995 in England, Scotland, Wales and Finland. These countries also have the highest incidence of alcohol related liver disease in east and north eastern European countries.
Alcohol also has a significant socio-economic impact, costing more than €155 billion annually and posing a real threat to the European healthcare system. As a result, UEG considers alcohol and its relationship with GI diseases an urgent research priority.UEG spokesperson and European Association for the Study of the Liver (EASL) member, Professor Patrizia Burra explains, “There is a need to develop specific therapies for the treatment of patients with alcoholic liver disease, especially as it is the second leading risk factor for disease burden in Europe.
“Excessive alcohol consumption amongst young people is also a growing concern and cost-effective prevention programmes must be implemented and novel treatments developed to enable us to tackle liver disease and reduce deaths from liver cancer across Europe,” adds Prof. Burra.
Follow UEG’s tips on how to drink safely and reduce the risk of developing liver disease and cancer:

Have 2-3 alcohol-free days a week to allow the liver time to repair itself.

Men: Drink no more than 3-4 alcoholic drinks on any day (equivalent to 852ml of beer/250ml of wine) and a maximum of 21 drinks in any week.

Women: Drink no more than 2-3 alcoholic drinks on any day (equivalent to 568ml beer/175ml of wine) and a maximum of 14 drinks in any week.

Be symptom smart and seek medical advice if you experience pain in the lower right hand side of your ribs, general nausea and lack of energy.

Protect yourself from blood-borne viruses Hepatitis B and Hepatitis C infections which can lead to liver cancer.

Notes to Editors
About AWARH
The European Awareness Week on Alcohol Related Harm (AWARH) was initiated in 2013 to call for the renewal of the EU Alcohol Strategy. During AWARH’13, healthcare stakeholders presented the Roundtable Conclusions on Reducing Alcohol Related Harm and MEPs opened discussions on working collaboratively on the need to renew the EU Alcohol Strategy.
The week will end with the 6th European Alcohol Policy Conference in Brussels (27th and 28th November). Throughout the Conference, UEG will be present with a booth to make known the harmful impact of alcohol intake on the gastrointestinal system.
Further information about AWARH and the different activities which will take place during the week can be found at www.awarh.eu #AWARH14
About UEG
UEG, or United European Gastroenterology, is a professional non-profit organisation combining all the leading European societies concerned with digestive diseases. Together, its member societies represent over 22,000 specialists, working across medicine, surgery, paediatrics, gastrointestinal oncology and endoscopy. This makes UEG the most comprehensive organisation of its kind in the world, and a unique platform for collaboration and the exchange of knowledge.
Find out more about UEG’s work. Visit www.ueg.eu
Available for interviewProfessor Patrizia Burra, Head Multivisceral Transplant Unit, Gastroenterology Department of Surgery, Oncology and Gastroenterology, Padova University Hospital and member of The European Association for the Study of the Liver (EASL).
Press contact
Samantha Forster
media@ueg.eu
Tel: +44(0)1444 811099
@UEGMedia
References:
1. The International Agency for Research on Cancer. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. Lyon, France: IARC; 2013 Dec Available from: http://globocan.iarc.fr/2. United European Gastroenterology, 2014, Survey of Digestive Health across Europe http://ueg.sagepub.com/site/White_Book/White_Book.xhtml3. WHO-Europe, 2012, Alcohol in the European Union – consumption, harm and policy approaches, http://ec.europa.eu/health/alcohol/docs/who_alcoholintheeu_2012_en.pdf4. https://www.drinkaware.co.uk/

What will the European healthcare system look like in 2040?

(Vienna, October 21, 2014) United European Gastroenterology (UEG) has today launched ‘Future Scenarios’, three plausible models for future healthcare delivery in Europe, to encourage healthcare professionals and policy makers to start planning for a more sustainable future for patients with digestive and liver diseases.

These ‘Future Scenarios’, which have taken more than a year to develop, will challenge current thinking and aim to inspire the gastroenterology community to work together to shape a better future for patients.

“Current models for healthcare delivery in Europe are unsustainable, with a rapidly ageing population, volatile political and economic landscapes as well as a shrinking workforce and increasing lifestyle diseases,” says UEG President, Professor Michael Farthing. “If we don’t start planning for change now, we are all going to be facing a pretty uncertain future.”
Unsustainable burden of GI diseases
Gastrointestinal (GI) diseases contribute significantly to the healthcare burden in Europe, accounting for substantial morbidity, mortality and cost. Digestive diseases - gastrointestinal and liver disorders - are common across Europe, causing more than 500,000 deaths in 2008 in the 28 EU member states (and more than 900,000 deaths in the whole of Europe, including Russia and other non-EU states). Over one-third of all acute hospital admissions are due to GI diseases and most Europeans will visit a gastroenterologist at least once in their lives.
“We know that the incidence and prevalence of most major GI disorders are rising across Europe and there is already poor access to care in many countries,” said Prof. Farthing. “Since changing the way we deliver healthcare in the future seems inevitable, we decided to take a bold approach and highlight possible scenarios, inspiring everyone to get involved and play their part in shaping a better future for digestive and liver disease healthcare.”
Healthcare in Europe 2040: Scenarios and implications for digestive and liver diseases
Over the past year, UEG’s Future Scenarios Working Group has been collaborating with specialist scenario planners to develop a set of plausible, relevant and challenging scenarios that may impact the delivery of GI healthcare in 2040. These scenarios – entitled Ice Age, Silicon Age and Golden Age – will be launched today at UEG Week 2014, with more than 600 gastro and liver disease specialists as well as a wide range of stakeholder groups joining the debate.
The healthcare scenarios for 2040 to be launched are:
· Ice Age: Where European impoverishment will have led to two-tier medicine and eventually to the collapse of public healthcare in Europe.
· Silicon Age: Where advancements in technology, science and social interactions will have led to very extensive automation of diagnoses and treatments and redirected health behaviour, resulting in a positive change in healthcare.
· Golden Age: Where a strong, well-coordinated, unified Europe will ensure high-quality healthcare for ALL European citizens.
“The three scenarios we have developed, which could all form the shape of healthcare in Europe in 2040, will help focus our thinking and encourage us to have courageous conversations about the future of gastroenterology practice,” said Prof. Farthing. “We see today’s launch as the start of those conversations and hope everyone will join the debate and work together to deliver high-quality care whatever the future holds.”
Starting the Conversation
Help us plan for a better future for people with digestive and liver diseases
Visit www.ueg.eu/research/gi2040/ and vote for the scenario you think is most likely.
Post your thoughts and comments on the future of digestive and liver diseases throughout Europe @my_UEG #GI2040.
Notes to Editors
About UEG Week
UEG Week is the largest and most prestigious gastroenterology meeting in Europe and has developed into a global congress. It attracts over 14,000 participants each year, from more than 120 countries, and numbers are steadily rising. UEG Week provides a forum for basic and clinical scientists from across the globe to present their latest research in digestive and liver diseases, and also features a two-day postgraduate course that brings together top lecturers in their fields for a weekend of interactive learning.
From October 18-22, 2014, UEG will connect everyone to its annual meeting via livestream on www.ueg.eu. State-of-the-art lectures of Europe’s largest GI meeting may be followed online from around the world. Include #UEGWeek in your tweets. UEG Week 24/7 features all recorded sessions from UEG Week and provides convenient and direct access to the complete congress material, including E-posters and abstracts.
About UEG
UEG, or United European Gastroenterology, is a professional non-profit organisation combining all the leading European societies concerned with digestive diseases. Together, its member societies represent over 22,000 specialists, working across medicine, surgery, paediatrics, gastrointestinal oncology and endoscopy. This makes UEG the most comprehensive organisation of its kind in the world, and a unique platform for collaboration and the exchange of knowledge.
To advance standards of gastroenterological care and knowledge across Europe and the world, UEG offers numerous activities and initiatives besides UEG Week, including:
· UEG Education, the universal source of knowledge in gastroenterology, providing online and classroom courses, a huge online library and delivering the latest GI news, fostering debate and discussion
· Training Support, funding for innovative training and educational programmes, as well as international scientific and professional co-operations
· UEG Journal, published bi-monthly, covering translational and clinical studies from all areas of gastroenterology
· EU Affairs, promoting research, prevention, early diagnosis and treatment of digestive diseases, and helping develop an effective health policy for Europe
Find out more about UEG’s work. Visit www.ueg.eu
Follow UEG on Twitter @my_ueg and @UEGMedia
Press Contacts
Samantha Forster
Email: media@ueg.eu
Tel: +44 (0)1444 811099
Press Release TranslationsDownload press release
Download der Pressemitteilung
Descarga nota de prensa
Télécharger le communiqué de presse
Download comunicato stampa
Download プレスリリース
Download 新闻稿

(Vienna, October 22, 2014) The search for blood-borne biomarkers that could be used to screen for colorectal cancer (CRC) has uncovered two promising candidates that may one day lead to the development of a simple blood test.

Scientists have been piecing together the molecular events involved in the development of CRC and have identified abnormal DNA methylation patterns and the presence of microRNAs as major players in the carcinogenic process.

Speaking to journalists at the 22nd United European Gastroenterology Week (UEG Week 2014) in Vienna, Austria, Dr Antonio Castells from the Institute of Digestive Diseases Hospital Clinic in Barcelona, Spain, said these were exciting times to be working in CRC biomarker research. “Blood-borne biomarkers are opening up exciting avenues of investigation in colorectal and other cancers,” he said. “We now have a better understanding of the molecular events participating in the development of CRC and these provide valuable targets for both the early detection of CRC and the development of novel treatments.”
CRC screening: why do we need a blood test?
Colorectal cancer is the third most common cancer worldwide and the second leading cause of cancer-related death in the Western world. Several studies have confirmed that CRC screening is both effective and cost-effective in the average-risk population, with the two recommended strategies being stool tests that identify occult blood or exfoliated DNA associated with cancer, and structural examinations such as colonoscopy that detect both cancer and pre-malignant lesions.
“Participation in CRC screening programmes across Europe is worryingly low and there seems little doubt that people are put off by the nature of the current tests,” said Dr Castells. “A simple blood test would encourage more people to come forward for screening, potentially saving thousands of lives every year.”
The search for CRC screening biomarkers
Cancer biomarkers are biological changes that signal the presence of cancer in the body and are usually related to alterations in DNA, RNA or protein expression.1 Several protein biomarkers of CRC have already been identified, however, none have been useful for CRC screening.1 More recently, researchers investigating tumour-derived DNA in the blood have observed abnormal DNA methylation patterns – specifically, abnormally methylated SEPT9 DNA – in the patients with CRC, suggesting a potential new DNA-based biomarker for screening.1
The second potential screening approach outlined by Dr Castells involves assessing the profile of small, non-coding RNAs, known as microRNAs, which have been shown to be increased in the plasma from patients with CRC.2 A recent study conducted by Dr Castells and colleagues found that patients with CRC or advanced adenomas had a significantly different pattern of microRNA expression compared with healthy individuals, leading the group to conclude that plasma microRNA testing was a promising screening test for CRC that warrants further investigation.2
“Both of these potential new CRC screening approaches have shown promise in preliminary studies and should be explored further in larger cohorts of patients,” he told journalists. “There is no doubt in my mind that having an accurate, blood-based screening method would increase adherence to CRC screening guidelines and reduce the number of patients reluctant to be screened.”
References1. Summers T, et al. J Cancer 2013; 4: 210–216.2. Giráldez MD, et al. Clin Gastroenterol Hepatol 2013;11: 681–688.e3. Notes to Editors
About UEG Week
UEG Week is the largest and most prestigious gastroenterology meeting in Europe and has developed into a global congress. It attracts over 14,000 participants each year, from more than 120 countries, and numbers are steadily rising. UEG Week provides a forum for basic and clinical scientists from across the globe to present their latest research in digestive and liver diseases, and also features a two-day postgraduate course that brings together top lecturers in their fields for a weekend of interactive learning.
From October 18-22, 2014, UEG will connect everyone to its annual meeting via livestream on www.ueg.eu. State-of-the-art lectures of Europe’s largest GI meeting may be followed online from around the world. Include #UEGWeek in your tweets. UEG Week 24/7 features all recorded sessions from UEG Week and provides convenient and direct access to the complete congress material, including E-posters and abstracts.
About UEG
UEG, or United European Gastroenterology, is a professional non-profit organisation combining all the leading European societies concerned with digestive diseases. Together, its member societies represent over 22,000 specialists, working across medicine, surgery, paediatrics, gastrointestinal oncology and endoscopy. This makes UEG the most comprehensive organisation of its kind in the world, and a unique platform for collaboration and the exchange of knowledge.
To advance standards of gastroenterological care and knowledge across Europe and the world, UEG offers numerous activities and initiatives besides UEG Week, including:
· UEG Education, the universal source of knowledge in gastroenterology, providing online and classroom courses, a huge online library and delivering the latest GI news, fostering debate and discussion
· Training Support, funding for innovative training and educational programmes, as well as international scientific and professional co-operations
· UEG Journal, published bi-monthly, covering translational and clinical studies from all areas of gastroenterology
· EU Affairs, promoting research, prevention, early diagnosis and treatment of digestive diseases, and helping develop an effective health policy for Europe
Find out more about UEG’s work. Visit www.ueg.eu
Follow UEG on Twitter @my_ueg and @UEGMedia
Press Contacts
Samantha Forster
Email: media@ueg.eu
Tel: +44 (0)1444 811099
Press Release TranslationsDownload press release
Download der Pressemitteilung
Descarga nota de prensa
Télécharger le communiqué de presse
Download comunicato stampa
Download プレスリリース
Download 新闻稿

UK expert highlights research innovation and is optimistic about the future of IBS treatment.

(Vienna, October 21, 2014) Patients with irritable bowel syndrome (IBS) may at last be able to hope for a brighter future as innovative new treatments emerge and researchers clarify the role of current therapies.

Dr Alexander C. Ford from the Leeds Gastroenterology Institute in Leeds, UK, tells journalists attending the 22nd United European Gastroenterology Week (UEG Week 2014) in Vienna, Austria, that significant progress was being made in drug development for IBS, thanks to the intense research efforts of scientists around the world. “Researchers have dedicated many years to the task of unravelling the pathophysiology of IBS, and it’s thanks to these efforts that novel molecular therapies are now in development,” he says.

Current therapies for IBS
IBS is a chronic, relapsing–remitting functional disorder of the gastrointestinal tract, estimated to affect between 5% and 20% of the general population. The symptoms of IBS include recurrent abdominal pain or discomfort and changes in bowel habit, including diarrhoea and/or constipation. Treatment is typically targeted towards the predominant symptoms, with increased intake of soluble fibre and antispasmodic agents frequently used as first-line therapies. Other treatment options with proven efficacy in IBS include certain antidepressants, psychological therapies such as cognitive behavioural therapy and hypnotherapy, and some probiotics.1
“We currently have a number of fairly effective short-term treatments available for patients with IBS, but, unfortunately, no drug treatment has so far been shown to alter the clinical course of IBS, and the long-term efficacy of current therapies is still unknown,” says Dr Ford.
Emerging drug therapies
Several promising new types of drug therapy have emerged in recent years for the treatment of IBS. Pro-secretory agents have been found to be effective in constipation-predominant IBS although their precise roles in the IBS treatment algorithm is not yet determined. Bile acid modulators are currently under investigation in IBS patients, with initial studies suggesting efficacy in constipation-predominant IBS.
“The number of novel agents in clinical development for the treatment of IBS is a clear reflection of our growing understanding of the pathogenesis of the condition, but it also demonstrates the extent of the unmet medical need,” he says. “I think with the intensity of the research effort going into new IBS treatments, we can be optimistic for both IBS sufferers and the physicians who treat them.”
Notes to Editors
About UEG Week
UEG Week is the largest and most prestigious gastroenterology meeting in Europe and has developed into a global congress. It attracts over 14,000 participants each year, from more than 120 countries, and numbers are steadily rising. UEG Week provides a forum for basic and clinical scientists from across the globe to present their latest research in digestive and liver diseases, and also features a two-day postgraduate course that brings together top lecturers in their fields for a weekend of interactive learning.
From October 18-22, 2014, UEG will connect everyone to its annual meeting via livestream on www.ueg.eu. State-of-the-art lectures of Europe’s largest GI meeting may be followed online from around the world. Include #UEGWeek in your tweets. UEG Week 24/7 features all recorded sessions from UEG Week and provides convenient and direct access to the complete congress material, including E-posters and abstracts.
About UEG
UEG, or United European Gastroenterology, is a professional non-profit organisation combining all the leading European societies concerned with digestive diseases. Together, its member societies represent over 22,000 specialists, working across medicine, surgery, paediatrics, gastrointestinal oncology and endoscopy. This makes UEG the most comprehensive organisation of its kind in the world, and a unique platform for collaboration and the exchange of knowledge.
To advance standards of gastroenterological care and knowledge across Europe and the world, UEG offers numerous activities and initiatives besides UEG Week, including:
· UEG Education, the universal source of knowledge in gastroenterology, providing online and classroom courses, a huge online library and delivering the latest GI news, fostering debate and discussion
· Training Support, funding for innovative training and educational programmes, as well as international scientific and professional co-operations
· UEG Journal, published bi-monthly, covering translational and clinical studies from all areas of gastroenterology
· EU Affairs, promoting research, prevention, early diagnosis and treatment of digestive diseases, and helping develop an effective health policy for Europe
Find out more about UEG’s work. Visit www.ueg.eu
Follow UEG on Twitter @my_ueg and @UEGMedia
Press Contacts
Samantha Forster
Email: media@ueg.eu
Tel: +44 (0)1444 811099
Press Release TranslationsDownload press release
Download der Pressemitteilung
Descarga nota de prensa
Télécharger le communiqué de presse
Download comunicato stampa
Download プレスリリース
Download 新闻稿

(Vienna, October 20, 2014) A major pan-European survey into the burden of gastrointestinal (GI) disorders and the delivery of care has revealed changing trends in many important GI and liver diseases and worrying inequalities in the provision of healthcare services across the continent.

The results of the survey, which was commissioned by United European Gastroenterology (UEG), have been announced today and led to calls for greater political and public awareness of the burden of GI disorders across Europe and for more funding to be made available to improve service provision and support Europe-wide research.

“This extensive survey has highlighted major differences between countries in terms of both the risk of developing GI disorders and their long-term health outcomes,” said UEG President, Professor Michael Farthing. “We are particularly concerned about the increasing incidence of most major GI disorders across Europe and the clear differences in outcomes for patients between Eastern and Western nations.”
Survey of Digestive Health Across Europe1,2
The Survey of Digestive Health Across Europe was commissioned by UEG in the spring of 2013 at the request of its own Future Trends Committee. Experienced research teams from the College of Medicine at Swansea University in Wales, UK, initiated a detailed assessment of digestive health across Europe, focussing on the clinical and economic burden of disease and the organisation and delivery of gastroenterology services across 28 European Union (EU) member states, Norway, Switzerland, Liechtenstein and Russia. The aim of the survey was draw to together all the available evidence and provide up-to-date information on the human health consequences and public health burden of GI disorders.
“Gastroenterology is a medical specialty that gets relatively little attention from a policy perspective compared with other specialties and attracts minimal independent research funding,” said Professor Farthing. “We wanted to take a long, hard look at the situation today across Europe in order to ensure we prioritise our efforts where it is needed most.”
Changing trends in GI disorders
The Digestive Health survey revealed a number of evolving trends in terms of the incidence and prevalence of GI disorders. According to the survey results, most European countries have witnessed increases in the incidence of major GI disorders such as upper GI bleeding, inflammatory bowel disease [IBD], coeliac disease, alcoholic liver disease, gallstone disease, and colorectal and oesophageal cancer, with disease rates highest amongst older people. Incidence or prevalence rates were found to be higher in most Eastern European countries compared with other regions in Europe, with mortality from GI disorders (other than cancer and infectious diseases) highest in Eastern and North Eastern countries and lowest in parts of Scandinavia and the Mediterranean Islands.
GI cancer is now the leading cause of cancer death in Europe, and while mortality rates for colorectal cancer (CRC) have fallen for several decades in almost all Western, Northern and Central European countries, rates continue to rise in many parts of Eastern Europe and some parts of Southern Europe. “We need to look more closely at the reasons behind these worrying statistics and find ways to overcome the regional differences observed and reduce the growing burden of GI cancers,” said Professor Farthing.
Inequalities in healthcare provision
The survey identified major inequalities in healthcare provision across Europe. While CRC screening programmes are now well established in most European countries, participation rates vary widely and there is no standardised approach to screening. Upper GI bleeding is managed variably across Europe, with a lack of consensus on best practice. Endoscopy services are patchy and not currently viewed as a priority by policymakers, which could have serious implications for meeting future service demands. Training of medical students in gastroenterology varies between countries and is poorly documented.
“This survey was wide-ranging and has highlighted some areas of good practice, but many areas that require attention at both a national and European level,” said Professor Farthing. “Our hope is that, ultimately, the survey and the reports generated will help to improve care and health outcomes and reduce inequalities across the continent.”
References1. Roberts SE, Samuel DG, Williams JG, et al. Survey of Digestive Health across Europe. Part one: The burden of gastrointestinal diseases and the organisation and delivery of gastroenterology services across Europe. Report for United European Gastroenterology. October 2014. 2. Anderson P, Fitzsimmons D, Hale J, et al.. Survey of Digestive Health across Europe. Part two: The economic impact and burden of gastrointestinal diseases across Europe. Report for United European Gastroenterology. October 2014. Notes to Editors
About UEG Week
UEG Week is the largest and most prestigious gastroenterology meeting in Europe and has developed into a global congress. It attracts over 14,000 participants each year, from more than 120 countries, and numbers are steadily rising. UEG Week provides a forum for basic and clinical scientists from across the globe to present their latest research in digestive and liver diseases, and also features a two-day postgraduate course that brings together top lecturers in their fields for a weekend of interactive learning.
From October 18-22, 2014, UEG will connect everyone to its annual meeting via livestream on www.ueg.eu. State-of-the-art lectures of Europe’s largest GI meeting may be followed online from around the world. Include #UEGWeek in your tweets. UEG Week 24/7 features all recorded sessions from UEG Week and provides convenient and direct access to the complete congress material, including E-posters and abstracts.
About UEG
UEG, or United European Gastroenterology, is a professional non-profit organisation combining all the leading European societies concerned with digestive diseases. Together, its member societies represent over 22,000 specialists, working across medicine, surgery, paediatrics, gastrointestinal oncology and endoscopy. This makes UEG the most comprehensive organisation of its kind in the world, and a unique platform for collaboration and the exchange of knowledge.
To advance standards of gastroenterological care and knowledge across Europe and the world, UEG offers numerous activities and initiatives besides UEG Week, including:
· UEG Education, the universal source of knowledge in gastroenterology, providing online and classroom courses, a huge online library and delivering the latest GI news, fostering debate and discussion
· Training Support, funding for innovative training and educational programmes, as well as international scientific and professional co-operations
· UEG Journal, published bi-monthly, covering translational and clinical studies from all areas of gastroenterology
· EU Affairs, promoting research, prevention, early diagnosis and treatment of digestive diseases, and helping develop an effective health policy for Europe
Find out more about UEG’s work. Visit www.ueg.eu
Follow UEG on Twitter @my_ueg and @UEGMedia
Press Contacts
Samantha Forster
Email: media@ueg.eu
Tel: +44 (0)1444 811099
Press Release TranslationsDownload press release
Download der Pressemitteilung
Descarga nota de prensa
Télécharger le communiqué de presse
Download comunicato stampa
Download プレスリリース
Download 新闻稿

(Vienna, October 17, 2014) Two new pill-only regimens that rapidly cure most patients with genotype 1 hepatitis C (HCV) infection could soon be widely prescribed across Europe. Two recently-published studies confirmed the efficacy and safety of combination therapy with two oral direct-acting antiviral agents (DAAs), with around 90% of patients cured after just 12-weeks of treatment.

At the 22nd United European Gastroenterology Week (UEG Week 2014) in Vienna, Austria, Professor Michael P. Manns from Hannover Medical School in Germany will be presenting this data and says this represents a massive step forward in the treatment of this life-threatening infection. “These new pill-only regimens have the potential to offer more effective, safer and faster virus eradication than current therapies, even in traditionally hard-to-cure patients,” he says. “We hope that a pill-only regimen will encourage more people to come forward and accept treatment so we can one day eradicate this deadly virus.”Burden of hepatitis C infection
Hepatitis C virus (HCV) infection is a global epidemic, with more than 180 million people thought to have chronic HCV infection worldwide. HCV genotype 1 represents the majority of infections in Europe and is considered the most difficult to cure. Until recently, the standard of care for chronic HCV genotype 1 infection involved a combination of drugs, was associated with severe side-effects and involved complicated injection and tablet regimens lasting up to 1 year.
“These treatment regimens, although effective, are difficult to manage and poorly tolerated by many patients, and some clinicians won’t even use them,” says Prof. Manns. “We desperately need simpler treatment regimens that are highly effective, that can be used in more patients, and that do not cause such severe toxicity.”
New pill-only regimens
Two recently-published studies used different combinations of oral antivirals to treat patients with chronic HCV genotype 1 infection. In the first study – called the HALLMARK-DUAL study1 – 645 patients with HCV genotype 1b infection received an NS3 protease inhibitor twice-daily plus once-daily NS5A replication complex inhibitor or placebo. Twelve weeks after the end of a 24 week treatment period (the primary endpoint), the combination regimen had provided a sustained virological response (SVR) – which is considered a cure – in 90% of previously untreated patients and 82% of patients who had failed to respond to, or could not tolerate, their previous treatment.
“This is a vast improvement over standard triple therapy, with efficacy observed across the board – even in patients with liver cirrhosis and those who have failed other treatments,” says Prof. Manns. “The combination treatment was also well tolerated by most patients.”
In a second study – called the COSMOS study2 – 167 patients with HCV genotype 1a and 1b infection were randomized and treated with a second generation NS3/4A protease inhibitor once-daily plus a NS5B polymerase inhibitor once-daily with or without ribavirin. After 12 weeks of treatment, 93% of patients (including those with cirrhosis and interferon non-responders) had achieved an SVR. Again, the combination regimen was well tolerated, with less than 2% of patients reporting serious adverse events or withdrawing from treatment because of adverse events.
“The results from these two studies suggest that interferon- and ribavirin- based treatment for chronic HCV infection may soon become a thing of the past,” says Prof. Manns. “With several more pill only regimens having also been reported this year, this is a key moment in the history of HCV treatment and represents an important step towards universally effective, needle-free treatments for HCV.”3,4,5.
References1. Manns M, et al. Lancet. E-Pub:Jul 26 2014 http://dx.doi.org/10.1016/S0140-6736(14)61059-X
2. Lawitz E, et al. The Lancet 2014: 383: 9916:515-523
3. Afdhal N, et al, NEJM 2014: 370:1483-149
4. Feld J, et al, NEJM 2014: 370:1594-603
5. Sulkowski M, , NEJM 2014: 370:222-232
Notes to Editors
About UEG Week
UEG Week is the largest and most prestigious gastroenterology meeting in Europe and has developed into a global congress. It attracts over 14,000 participants each year, from more than 120 countries, and numbers are steadily rising. UEG Week provides a forum for basic and clinical scientists from across the globe to present their latest research in digestive and liver diseases, and also features a two-day postgraduate course that brings together top lecturers in their fields for a weekend of interactive learning.
From October 18-22, 2014, UEG will connect everyone to its annual meeting via livestream on www.ueg.eu. State-of-the-art lectures of Europe’s largest GI meeting may be followed online from around the world. Include #UEGWeek in your tweets. UEG Week 24/7 features all recorded sessions from UEG Week and provides convenient and direct access to the complete congress material, including E-posters and abstracts.
About UEG
UEG, or United European Gastroenterology, is a professional non-profit organisation combining all the leading European societies concerned with digestive diseases. Together, its member societies represent over 22,000 specialists, working across medicine, surgery, paediatrics, gastrointestinal oncology and endoscopy. This makes UEG the most comprehensive organisation of its kind in the world, and a unique platform for collaboration and the exchange of knowledge.
To advance standards of gastroenterological care and knowledge across Europe and the world, UEG offers numerous activities and initiatives besides UEG Week, including:
· UEG Education, the universal source of knowledge in gastroenterology, providing online and classroom courses, a huge online library and delivering the latest GI news, fostering debate and discussion
· Training Support, funding for innovative training and educational programmes, as well as international scientific and professional co-operations
· UEG Journal, published bi-monthly, covering translational and clinical studies from all areas of gastroenterology
· EU Affairs, promoting research, prevention, early diagnosis and treatment of digestive diseases, and helping develop an effective health policy for Europe
Find out more about UEG’s work. Visit www.ueg.eu
Follow UEG on Twitter @my_ueg and @UEGMedia
Press Contacts
Samantha Forster
Email: media@ueg.eu
Tel: +44 (0)1444 811099
Press Release TranslationsDownload press release
Download der Pressemitteilung
Descarga nota de prensa
Télécharger le communiqué de presse
Download comunicato stampa
Download プレスリリース
Download 新闻稿

New e-learning developments shaping the future of gastroenterology and hepatology.

(Vienna, October 08, 2014) Ahead of UEG Week 2014, Vienna (18 October – 22nd October 2014) United European Gastroenterology (UEG) are delighted to announce their new and improved e-learning portal, providing a unique education platform with exciting innovations for the gastroenterology and hepatology community.

The UEG e-learning portal has grown exponentially and now includes thousands of categorised and searchable documents, media clips, CME courses as well as meeting content. As Dr Charles Murray, gastroenterologist at London’s Royal Free Hospital and Chair of UEG’s e-learning Taskforce, explains in the October edition of the UEG Journal, “The strength and advantage of the UEG educational platform is that the UEG Member Societies and UEG National Society Members feed into it, shaping a unique and comprehensive portal with extensive GI-related material and educational resources.”
UEG provides high quality, accessible and independent education and training in gastroenterology. We carry out a range of activities, including training courses (both as e-learning and hands-on residential courses), hosting a huge online library and providing the latest GI news, fostering debate and discussion.
“UEG now look to improving their educational resources. We aim to do so by further engagement with Member Societies and National Societies through sharing of information, research and news and look forward to any ideas from members and specialists. UEG Education is at the beginning of an exciting stage in its development and we value input in shaping the future,” adds Dr Charles Murray.
Throughout UEG Week in Vienna (18 October – 22nd October) attendees will be able to visit the UEG Education Lounge, a dedicated area at the Congress providing free access to UEG’s educational activities including the e- learning platform.
UEG Week 24/7 – is a dedicated area on the UEG website, which also provides access to abstracts, e-posters and recordings from UEG Week all year round, allowing the whole gastroenterological community access to unrivalled expertise and knowledge anywhere and at any time.
Notes to Editors
About UEG Week
UEG Week is the largest and most prestigious gastroenterology meeting in Europe and has developed into a global congress. It attracts over 14,000 participants each year, from more than 120 countries, and numbers are steadily rising. UEG Week provides a forum for basic and clinical scientists from across the globe to present their latest research in digestive and liver diseases, and also features a two-day postgraduate course that brings together top lecturers in their fields for a weekend of interactive learning.
From October 18-22, 2014, UEG will connect everyone to its annual meeting via livestream on www.ueg.eu. State-of-the-art lectures of Europe’s largest GI meeting may be followed online from around the world. Include #UEGWeek in your tweets. UEG Week 24/7 features all recorded sessions from UEG Week and provides convenient and direct access to the complete congress material, including E-posters and abstracts.
About UEG
UEG, or United European Gastroenterology, is a professional non-profit organisation combining all the leading European societies concerned with digestive diseases. Together, its member societies represent over 22,000 specialists, working across medicine, surgery, paediatrics, gastrointestinal oncology and endoscopy. This makes UEG the most comprehensive organisation of its kind in the world, and a unique platform for collaboration and the exchange of knowledge.
To advance standards of gastroenterological care and knowledge across Europe and the world, UEG offers numerous activities and initiatives besides UEG Week, including:
· UEG Education, the universal source of knowledge in gastroenterology, providing online and classroom courses, a huge online library and delivering the latest GI news, fostering debate and discussion
· Training Support, funding for innovative training and educational programmes, as well as international scientific and professional co-operations
· UEG Journal, published bi-monthly, covering translational and clinical studies from all areas of gastroenterology
· EU Affairs, promoting research, prevention, early diagnosis and treatment of digestive diseases, and helping develop an effective health policy for Europe
Find out more about UEG’s work. Visit www.ueg.eu
Follow UEG on Twitter @my_ueg and @UEGMedia
Press Contacts
Samantha Forster
Email: media@ueg.eu
Tel: +44 (0)1444 811099

Study finds link between depression and abnormal brain response to visceral pain in patients with IBS.

(Vienna, October 02, 2014) High rates of anxiety and depression amongst patients with irritable bowel syndrome (IBS) have led many researchers to believe there could be a causal relationship between psychological factors and IBS symptoms.

Now, scientists in Germany have found clear evidence that patients with IBS process pain signals from the gut abnormally, and that disturbed brain responses to pain are particularly pronounced in patients with more depression symptoms1.

At the 22nd United European Gastroenterology Week (UEG Week 2014) in Vienna, Austria, Professor Sigrid Elsenbruch from the University of Duisburg-Essen in Germany, will be presenting a new study which suggests that depression, but not anxiety, contributes to the abnormal pain processing observed in IBS in a model that addresses central pain inhibition during placebo analgesia. “Our study has shown that patients with IBS are less able to suppress pain signals in the brain coming from the bowel and that depression plays a role herein,” she says. “This study confirms the complex relationship between the gut and the brain and shows that affective disorders may contribute to the development or maintenance of disturbed pain processing in IBS.”
IBS, anxiety and depression
IBS is the most common functional gastrointestinal disorder with prevalence rates of up to 23% reported.2 The condition is characterised by recurrent abdominal pain or discomfort, in combination with bloating and altered bowel habits (e.g. diarrhoea and/or constipation). Depression and anxiety frequently co-exist with IBS, with a recent study reporting that 38% of IBS patients had clinically-confirmed depression (compared with 6% of healthy controls) and 32% had anxiety (compared with 13% of healthy controls).3
“The fact that so many people with IBS have anxiety and depression has led many to speculate that IBS is primarily a psychological, not a physical, disorder,” says Prof. Elsenbruch. “However, the condition is complex and most likely results from an interplay between psychological and biological factors. In fact, we don’t really know whether anxiety and depression result from having IBS or whether they contribute to the development or maintenance of symptoms. In many patients, both possibilities may be true at the same time.”
The “brain–gut” axis in IBS
There has been significant scientific interest in the role of central nervous system mechanisms along the “brain–gut” axis in IBS. Neuroimaging studies have demonstrated that neural processing of visceral stimuli (i.e. stimuli generated from internal organs such as the intestine) is altered in IBS, with many IBS patients showing lowered pain thresholds.4 In Prof. Elsenbruch’s latest study, painful rectal distensions were performed using a pressure-controlled barostat system in 17 patients with IBS and 17 sex- and age-matched healthy controls.1 Neural activation in pain-related brain areas was assessed using functional MRI (fMRI) while subjects received sequential intravenous administrations of saline and what they thought was an anti-spasmolytic drug (but was actually a saline placebo), in order to observe activation patterns during a typical placebo pain response.
The fMRI results in the healthy volunteers demonstrated reduced neural activation in pain-related brain areas during both the saline and sham treatment (placebo), indicating significant central pain inhibition. However, there was no such inhibition in the group of IBS patients, suggesting a deficiency in central pain inhibitory mechanisms in IBS. Interestingly, higher depression (but not anxiety) scores on the Hospital Anxiety and Depression Scale (HADS) were associated with reduced central pain inhibition in this study.
“Our findings suggest that patients with IBS do not process visceral pain signals in the same way as healthy people and are unable to suppress pain signals in the brain and, as a result, experience more pain from the same stimuli,” says Prof. Elsenbruch. “The fact that the presence of depression was associated with altered brain responses suggests that depression may contribute to these abnormal pain processes in IBS patients.”
References1. SchmidJ, et al. Gut 2014. May 15. pii: gutjnl-2013-306648. doi: 10.1136/gutjnl-2013-306648.2. www.aboutibs.org/site/what-is-ibs/facts/statistics3. Shah E, et al. Ann Gastroenterol 2014;27:224-30.4. Elsenbruch S. Brain Behav Immun 2011;25:386–94.Notes to Editors
About UEG Week
UEG Week is the largest and most prestigious gastroenterology meeting in Europe and has developed into a global congress. It attracts over 14,000 participants each year, from more than 120 countries, and numbers are steadily rising. UEG Week provides a forum for basic and clinical scientists from across the globe to present their latest research in digestive and liver diseases, and also features a two-day postgraduate course that brings together top lecturers in their fields for a weekend of interactive learning.
From October 18-22, 2014, UEG will connect everyone to its annual meeting via livestream on www.ueg.eu. State-of-the-art lectures of Europe’s largest GI meeting may be followed online from around the world. Include #UEGWeek in your tweets. UEG Week 24/7 features all recorded sessions from UEG Week and provides convenient and direct access to the complete congress material, including E-posters and abstracts.
About UEG
UEG, or United European Gastroenterology, is a professional non-profit organisation combining all the leading European societies concerned with digestive diseases. Together, its member societies represent over 22,000 specialists, working across medicine, surgery, paediatrics, gastrointestinal oncology and endoscopy. This makes UEG the most comprehensive organisation of its kind in the world, and a unique platform for collaboration and the exchange of knowledge.
To advance standards of gastroenterological care and knowledge across Europe and the world, UEG offers numerous activities and initiatives besides UEG Week, including:
· UEG Education, the universal source of knowledge in gastroenterology, providing online and classroom courses, a huge online library and delivering the latest GI news, fostering debate and discussion
· Training Support, funding for innovative training and educational programmes, as well as international scientific and professional co-operations
· UEG Journal, published bi-monthly, covering translational and clinical studies from all areas of gastroenterology
· EU Affairs, promoting research, prevention, early diagnosis and treatment of digestive diseases, and helping develop an effective health policy for Europe
Find out more about UEG’s work. Visit www.ueg.eu
Follow UEG on Twitter @my_ueg and @UEGMedia
Press Contacts
Samantha Forster
Email: media@ueg.eu
Tel: +44 (0)1444 811099
Press Release TranslationsDownload press release
Download der Pressemitteilung
Descarga nota de prensa
Télécharger le communiqué de presse
Download comunicato stampa
Download プレスリリース
Download 新闻稿